Technology
Health
Biotechnology

Syndax Pharmaceuticals

$7.32
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell SNDX and other stocks, options, ETFs, and crypto commission-free!

About

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. Read More The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Employees
38
Headquarters
Waltham, Massachusetts
Founded
2005
Market Cap
198.34M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
265.55K
High Today
$7.36
Low Today
$6.86
Open Price
$7.23
Volume
34.66K
52 Week High
$9.52
52 Week Low
$3.39

Collections

Technology
Health
Biotechnology
Cancer Prevention
2016 IPO
US
North America

News

Seeking AlphaMay 6

Syndax Pharmaceuticals, Inc. 2019 Q1 - Results - Earnings Call Slides

The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with their 2019 Q1 earnings call. 1 15 Click to enlarge Notes:...

69
Seeking AlphaMay 6

Syndax Pharmaceuticals' (SNDX) CEO Briggs Morrison on Q1 2019 Results - Earnings Call Transcript

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2019 Earnings Release and Conference Call May 6, 2019 4:30 PM ET Company Participants Melissa Forst – Argot Partners-Vice President Briggs Morrison – Chief Executive Officer Michael Metzger – President and Chief Operating Officer Rick Shea – Chief Financial Officer Peter Ordentlich – Chief Scientific Officer Michael Meyers – Chief Medical Officer Conference Call Participants Bert Hazlett – BTIG Madhu Kumar – R.W. Baird Chris Shibutani – Cowen Christo...

23
Yahoo FinanceMay 6

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates

Solar Capital (SLRC) delivered earnings and revenue surprises of 0.00% and -2.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

4

Earnings

-$0.96
-$0.82
-$0.67
-$0.53
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 6, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.